A national consortium of CLIA laboratories.
DMC coordinates one of the country's most respected networks of high-complexity laboratories — providing enterprise scale, geographic reach, and specialty capability under a single relationship.
One relationship. National coverage.
Through the DMC network, health systems and enterprise buyers gain access to specialized diagnostic capabilities across molecular oncology, infectious disease, toxicology, women's health, and anatomic pathology — without managing dozens of individual laboratory contracts.
Enterprise, specialty, and diverse-owned partners.
Enterprise partnerships
Large-volume reference and hospital-affiliated laboratories offering national menu breadth.
Specialty laboratories
Focused, high-complexity labs in molecular, genomics, pathology, and toxicology.
Diverse-owned laboratories
A growing consortium of minority-, woman-, and LGBTQIA+-owned CLIA labs — coordinated by DMC, a woman- and LGBTQIA+-owned firm — eligible for supplier diversity programs and enterprise contracts.
Coordinated capability, measurable outcomes.
- 01
Contracting scale
One negotiation, one MSA, one point of accountability across dozens of laboratory relationships. - 02
Specialty depth
Access to sub-specialty pathology, molecular, and reference testing without building it in-house. - 03
Supplier diversity
Meaningful engagement with minority-, woman-, and LGBTQIA+-owned laboratory partners — backed by a woman- and LGBTQIA+-owned coordinating firm. - 04
Quality governance
Uniform quality, accreditation, and turnaround standards enforced by DMC's operations team.